Novel concept of "sequential particle radiotherapy" with atezolizumab plus bevacizumab for hepatocellular carcinoma with portal vein tumor thrombus

Surg Today. 2024 Aug;54(8):972-976. doi: 10.1007/s00595-024-02805-1. Epub 2024 Mar 4.

Abstract

Owing to the high objective response rate of atezolizumab plus bevacizumab (Atez/Bev) for hepatocellular carcinoma (HCC), the concept of sequential conversion to local treatment has recently become mainstream. The conversion concept is mainly applied to Barcelona Clinic for Liver Cancer (BCLC) stage B cases, and radiotherapy is rarely considered as a conversion local treatment. We herein report three patients who were treated with the novel concept of "sequential particle radiotherapy," consisting of Atez/Bev therapy followed by particle radiotherapy (PRT) for HCC with advanced portal vein tumor thrombus (Vp3/4 PVTT). All patients achieved partial response radiologically and were switched to PRT. All patients were recurrence free at 1 year after the introduction of Atez/Bev therapy without any additional treatment. This upcoming combination strategy includes the advocacy of sequential concepts for BCLC stage C cases and the introduction of PRT as a local treatment after Atez/Bev.

Keywords: Atezolizumab plus bevacizumab; Hepatocellular carcinoma; Particle radiotherapy.

Publication types

  • Case Reports

MeSH terms

  • Aged
  • Antibodies, Monoclonal, Humanized* / administration & dosage
  • Antibodies, Monoclonal, Humanized* / therapeutic use
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use
  • Bevacizumab* / administration & dosage
  • Carcinoma, Hepatocellular* / therapy
  • Combined Modality Therapy
  • Female
  • Humans
  • Liver Neoplasms* / therapy
  • Male
  • Middle Aged
  • Neoplasm Staging
  • Neoplastic Cells, Circulating
  • Portal Vein*
  • Treatment Outcome
  • Venous Thrombosis / etiology

Substances

  • Bevacizumab
  • atezolizumab
  • Antibodies, Monoclonal, Humanized